Business Context and Reporting Period
Company: S&P Global Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 14, 2025
Principal Executive Offices: 55 Water Street, New York, NY 10041
This filing serves as a Regulation FD disclosure regarding a material corporate transaction announced via press release on the date of the report.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a strategic transaction rather than periodic financial performance data.
Material Changes
- Asset Divestiture: S&P Global Inc. has entered into an agreement to sell OSTTRA, a joint venture with CME Group Inc.
- Disclosure Method: Details regarding the transaction were disseminated through a press release attached as Exhibit 99.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release for transaction details but does not include specific management commentary, forward-looking guidance, or risk factors within the text of this 8-K form itself.
Legal Status of Information: Pursuant to general instruction B.2 to Form 8-K, the information furnished in this report (including the attached press release) is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. It shall not be incorporated by reference into other filings unless expressly set forth by specific reference.
Investor Verification Checklist
- Review the attached press release (Exhibit 99) for specific terms of the OSTTRA sale agreement.
- Verify the ownership structure and financial contribution of OSTTRA to S&P Global's prior earnings.
- Confirm the expected closing date and any regulatory approvals required for the divestiture.
- Assess the impact of the sale on future revenue streams and the relationship with CME Group Inc.